PTC Therapeutics | PTCT - Equity Capital And Reserves


PTC Therapeutics reported $-165.36M in Equity Capital and Reserves for its fiscal quarter ending in June of 2026.





Equity Capital And Reserves Change Date
Acadia Pharmaceuticals USD 1.31B 58.54M Jun/2026
Alnylam Pharmaceuticals USD 1.35B 278.74M Jun/2026
Amgen USD 11.69B 2.5B Jun/2026
BioCryst Pharmaceuticals USD -454.29M 99.55M Jun/2026
Biogen USD 18.85B 196.3M Jun/2026
BioMarin Pharmaceutical USD 6.32B 109.58M Jun/2026
Cytokinetics USD -173.49M 653.08M Jun/2026
Daiichi Sankyo JPY 1.7T 38.53B Jun/2026
Enanta Pharmaceuticals USD 126.59M 61.87M Dec/2025
Gilead Sciences USD 11.74B 11.77B Jun/2026
Incyte USD 6.34B 721.58M Jun/2026
Ionis Pharmaceuticals USD 439.74M 51.68M Jun/2026
Ironwood Pharmaceuticals USD -217.14M 44.69M Mar/2026
Karyopharm Therapeutics USD -265.65M 27.28M Mar/2026
Novartis USD 41.95B 3.02B Jun/2026
Pfizer USD 85.19B 4.91B Jun/2026
PTC Therapeutics USD -165.36M 15.1M Jun/2026
Puma Biotechnology USD 115.27M 10.55M Sep/2025
Roche Holding CHF 32.69B 1.11B Jun/2026
Sangamo BioSciences USD 19.6M 14.7M Jun/2025
Sarepta Therapeutics USD 1.53B 22.7M Jun/2026
TG Therapeutics USD 604.08M 20.95M Jun/2026
Ultragenyx Pharmaceutical USD -291M 55M Jun/2026
Vertex Pharmaceuticals USD 20.25B 886M Jun/2026
Xencor USD 503.23M 12.4M Jun/2026